A systematic review of PCSK9 inhibitors alirocumab and evolocumab

Medicine & Life Sciences

• alirocumab 100%
• evolocumab 99%
• Proprotein Convertase 9 87%
• oxidized low density lipoprotein 47%
• Systematic Reviews 43%
• Hyperlipoproteinemia Type II 29%
• Hydroxymethylglutaryl-CoA Reductase Inhibitors 23%
• Lipids 11%
• HDL Cholesterol 10%
• Health 8%
• Injection Site Reaction 8%
• Databases 7%
• LDL Cholesterol 5%
• Libraries 5%
• MEDLINE 5%
• Pharmaceutical Preparations 4%
• Decision Making 4%
• Cholesterol 4%
• Randomized Controlled Trials 3%
• Costs and Cost Analysis 3%
• Therapeutics 1%

Chemical Compounds

• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 85%
• High-Density Lipoprotein Cholesterol 46%
• Lipid 30%
• Strength 28%
• Low-Density Lipoprotein Cholesterol 23%
• Reduction 20%
• Drug 15%

Social Sciences

• evidence 24%
• health 7%
• drug 7%
• adverse events 7%
• quality good 6%
• event 6%
• medication 4%
• decision making 3%
• costs 3%
• market 3%
• Group 1%